Jennifer Curtis

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100546

N/A

0DataRank · unranked

18 citations

Zhenying Tan‐Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch +6 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

0DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2834

N/A

0DataRank · unranked

35 citations

Nabihah Tayob, Livius Penter, MacLean Sellars, Anna Tarren, Vipheaviny Chea +19 more

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5512

N/A

0DataRank · unranked

6 citations

Elizabeth Katherine Lee, Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, Andrea E. Wahner Hendrickson, D. Gulhan +14 more